Sargent Bickham Lagudis’s CRISPR Therapeutics CRSP Stock Holding History

Sargent Bickham Lagudis’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$7.28K	Buy	179 +50	+39%	+$2.65K	﹤0.01%	764
2022 Q3	$8K	Hold	129	–	–	﹤0.01%	719
2022 Q2	$8K	Hold	129	–	–	﹤0.01%	724
2022 Q1	$8K	Hold	129	–	–	﹤0.01%	738
2021 Q4	$10K	Buy	129 +97	+303%	+$8.47K	﹤0.01%	709
2021 Q3	$4K	Hold	32	–	–	﹤0.01%	826
2021 Q2	$5K	Hold	32	–	–	﹤0.01%	795
2021 Q1	$4K	Hold	32	–	–	﹤0.01%	810
2020 Q4	$5K	Hold	32	–	–	﹤0.01%	733
2020 Q3	$3K	Hold	32	–	–	﹤0.01%	698
2020 Q2	$2K	Hold	32	–	–	﹤0.01%	706
2020 Q1	$1K	Hold	32	–	–	﹤0.01%	733
2019 Q4	$2K	Hold	32	–	–	﹤0.01%	766
2019 Q3	$1K	Hold	32	–	–	﹤0.01%	691
2019 Q2	$2K	Hold	32	–	–	﹤0.01%	711
2019 Q1	$1K	Hold	32	–	–	﹤0.01%	776
2018 Q4	$1K	Hold	32	–	–	﹤0.01%	730
2018 Q3	$1K	Hold	32	–	–	﹤0.01%	742
2018 Q2	$2K	Buy	+32	New	+$1.82K	﹤0.01%	718

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sargent Bickham Lagudis's CRSP Position: Q4 2022 in Review

Sargent Bickham Lagudis increased its CRISPR Therapeutics (CRSP) stake by 39% in Q4 2022, buying an estimated $2.65K and bringing the position to 179 shares worth $7.28K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Sargent Bickham Lagudis first reported a position in CRSP in Q2 2018 and has held it in 19 quarters since. The position peaked at $10K in Q4 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Sargent Bickham Lagudis held 179 shares of CRISPR Therapeutics worth $7.28K as of Q4 2022.
Sargent Bickham Lagudis bought 50 CRISPR Therapeutics shares in Q4 2022, an estimated $2.65K.
CRISPR Therapeutics made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #764 holding.
Sargent Bickham Lagudis first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 19 quarters since.
Sargent Bickham Lagudis's CRISPR Therapeutics position peaked at $10K in Q4 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.